Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 5/20 | 0.69 |
| ▸ | ATR | Q13535 | 5/20 | 0.69 |
| ▸ | PRKCI | P41743 | 4/20 | 0.62 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | PRKDC | P78527 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3175503 | 0.86 | GRM4 (0.72) | GRM4ATRPRKCICYP2C9ALDH1A1 | |
| SCHEMBL15882338 | 0.83 | GRM4 (0.60) | GRM4ATRPRKCIPIM1PIM3 | |
| SCHEMBL13201028 | 0.81 | ATR (0.61) | GRM4ATRPRKCIPIM1MEN1 | |
| SCHEMBL28276095 | 0.81 | PRKCI (0.63) | GRM4ATRPRKCIMEN1ALDH1A1 | |
| SCHEMBL7974510 | 0.80 | ATR (0.59) | GRM4ATRPRKCIPIM1PIM3 | |
| SCHEMBL5936350 | 0.80 | HTT (0.60) | ATRPRKCICYP2C9MEN1ALDH1A1 | |
| SCHEMBL27212635 | 0.79 | GRM4 (0.55) | GRM4PIM1PIM3CYP2C9ALDH1A1 | |
| SCHEMBL1186799 | 0.79 | GRM4 (0.55) | GRM4ATRPRKCIPIM1PIM3 | |
| SCHEMBL9379517 | 0.78 | PRKCI (0.68) | GRM4ATRPRKCICYP2C9MEN1 | |
| SCHEMBL1228642 | 0.77 | GRM4 (0.54) | GRM4PIM1PIM3CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110272426-B | Alkynyl (hetero) aromatic ring compounds for inhibiting protein kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110194772-B | Alkynyl (hetero) aromatic ring compounds for inhibiting protein kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-108473476-B | Alkynyl heterocyclic compounds for inhibiting protein kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-110272426-A | For inhibiting (miscellaneous) the fragrant cyclics of the alkynyl of protein kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2019-09-24 | — | — | CN | disclosed |
| US-20110021541-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2011-01-27 | — | — | US | disclosed |
| US-20110021541-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2011-01-27 | — | — | US | disclosed |
| US-20110021541-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2011-01-27 | — | — | US | disclosed |
| EP-2220089-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009064802-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ELI LILLY & CO. (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064802-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ELI LILLY & CO. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021541-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | PIK3CD, PI4KB, PI4KA | GRM4 2840/4885ATR 1585/4885PRKCI 53/4885 |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | ABCC3, HCCS, ABCC2 | GRM4 4482/4885ATR 779/4885PRKCI 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.